Dynavax Technologies

Overview

Dynavax Technologies Corporation is a biopharmaceutical company based in Emeryville, California, founded in 1996. The company focuses on developing and commercializing vaccines and immunotherapies to protect against infectious diseases. Its flagship product, HEPLISAV-B, is a hepatitis B vaccine approved for adults, designed to prevent infection from all known subtypes of the virus. This vaccine utilizes CpG 1018, an adjuvant technology developed by Dynavax to enhance immune response, and is marketed primarily in the United States, with approvals in the European Union and Great Britain.

Dynavax has a robust pipeline of vaccine candidates in clinical development, including a plague vaccine and an investigational vaccine for shingles prevention. The company serves a diverse customer base, including hospitals, clinics, and government agencies, with distribution through wholesalers and specialty distributors. Under the leadership of CEO Ryan Spencer, Dynavax has expanded its commercial presence and invested significantly in research and development, reporting revenues exceeding $415 million in 2023. The company maintains strategic collaborations to support vaccine development and global distribution efforts.

Basic Information

Contact Details

• Phone: +1 510-848-5100
• Website: dynavax.com
• LinkedIn: linkedin.com/company/dynavax-technologies

Key Focus Areas & Initiatives

• Infectious diseases
• Biodefense
• Vaccine manufacturing & vaccines
• Biotechnology
• Pharmaceuticals
• Life sciences
• Biotechnology research
• Vaccines
• HEPLISAV-B
• Public health
• Biopharmaceutical industry
• Public health collaboration
• Vaccine safety
• Vaccine for shingles
• Infectious disease prevention
• Infectious disease vaccines
• Pharmaceutical and medicine manufacturing
• Vaccine manufacturing
• Global health
• International partnerships
• Plague vaccine
• Regulatory approvals
• Vaccine manufacturing technology
• Clinical pipeline
• Vaccine efficacy
• Vaccine pipeline
• Government
• Phase 1/2 clinical trials
• Public health institutions
• COVID-19 vaccine adjuvant
• Government collaborations
• Vaccine development
• B2B
• Vaccine for plague
• Shingles vaccine
• Two-dose hepatitis B vaccine
• Vaccine licensing
• Vaccine distribution
• CpG 1018
• Vaccine candidates
• Global vaccine access
• CpG 1018 adjuvant
• Clinical trials
• Vaccine commercialization
• Vaccine supply chain
• Adjuvant technology
• Biopharmaceutical
• Novel vaccines
• Hepatitis B vaccine
• Biopharmaceuticals
• Drug development
• Vaccine production
• FDA approved vaccines
• Vaccine market
• Immunization strategies
• Healthcare professionals
• Clinical research
• Biotech industry
• Regulatory affairs
• Investor relations
• Corporate governance
• Market share growth
• Employee engagement
• Team collaboration
• Community involvement
• Medical affairs
• Quality assurance
• Technical operations
• Business development
• Product pipelines
• Commercial execution
• Global health initiatives
• Hepatitis B prevention
• Clinical development
• Scientific advisory board
• Biotech innovation
• Vaccination recommendations
• Public health policies
• Healthcare
• Manufacturing
• Distribution
• Medical
• Health, wellness & fitness
• Health care
• Hospital & health care
• Mechanical or industrial engineering

Technologies Used

• Amazon AWS
• Apache
• Atlassian Cloud
• Bootstrap Framework
• Google Tag Manager
• Linkedin Marketing Solutions
• Microsoft Office 365
• Mimecast
• Mobile Friendly
• Outlook
• Pardot
• Remote
• Route 53
• Salesforce
• Typekit
• Vimeo

Affiliated Organizations & Regional Branches